Press & Media

Publications

Artificial Intelligence/Diamond AITM Platform

Immunotherapy

  • Chiriva-Internati, M., & Bot, A. (2015). A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System. International Reviews Of Immunology, 34(2), 101-103. doi:10.3109/08830185.2015.1015888 http://www.ncbi.nlm.nih.gov/pubmed/25901856
  • Grizzi, F., Mirandola, L., Qehajaj, D., Cobos, E., Figueroa, J. A., & Chiriva-Internati, M. (2015). Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity. International Reviews Of Immunology, 34(2), 143-153. doi:10.3109/08830185.2015.1018418 http://www.ncbi.nlm.nih.gov/pubmed/25901859
  • Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., & Chiriva-Internati, M. (2015). Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy. International Reviews Of Immunology, 34(2), 154-187. doi:10.3109/08830185.2015.1018419 http://www.ncbi.nlm.nih.gov/pubmed/25901860
  • Mirandola, L., Figueroa, J. A., Phan, T. T., Grizzi, F., Kim, M., Rahman, R. L., Chiriva-Internati, M. (2015). Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget, 6(5), 2812–2826. http://www.ncbi.nlm.nih.gov/pubmed/25739119
  • Chiriva-Internati, M., Mirandola, L., Yu, Y., Jenkins, M. R., Gornati, R., Bernardini, G., Cobos, E. (2011). Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother, 34(6), 490-499. doi:10.1097/CJI.0b013e31821ca76f http://www.ncbi.nlm.nih.gov/pubmed/21654522
  • Chiriva-Internati, M., Ferrari, R., Yuefei, Y., Hamrick, C., Gagliano, N., Grizzi, F., & Cobos, E. (2008). AKAP-4: a novel cancer testis antigen for multiple myeloma. British Journal Of Haematology, 140(4), 465-468. doi:10.1111/j.1365-2141.2007.06940.x http://www.ncbi.nlm.nih.gov/pubmed/18217892
  • Chiriva-Internati, M., Yu Y., Mirandola L., Jenkins M. R., Chapman C., Cannon M., Cobos E., Kast W. M. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868870/

BSK01

  1. Mirandola, L., Chiriva-Internati, M., Bresalier, R. et al. Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy. transl med commun 4, 17 (2019).
    https://doi.org/10.1186/s41231-019-0049-0.

BSK02™

  • Tawde, S. A., Chablani, L., Akalkotkar, A., D’Souza, C., Chiriva-Internati, M., Selvaraj, P., & D’Souza, M. J. (2012). Formulation and evaluation of oral microparticulate ovarian cancer vaccines. Vaccine, 30(38), 5675-5681. doi:10.1016/j.vaccine.2012.05.073 http://www.ncbi.nlm.nih.gov/pubmed/22750042

BSK02-ODP™

  • Chiriva-Internati, M., Pandey, A., Saba, R., Kim, M., Saadeh, C., Lukman, T., & Alalawi, R. (2012). Cancer Testis Antigens: A Novel Target in Lung Cancer. International Reviews Of Immunology, 31(5), 321-343. doi:10.3109/08830185.2012.723512 http://www.ncbi.nlm.nih.gov/pubmed/23083344
  • Pandey, A., Kurup, A., Shrivastava, A., Radhi, S., Nguyen, D. D., Arentz, C., Platonova, N. (2012). Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 31(5), 302-320. doi:10.3109/08830185.2012.723511 http://www.ncbi.nlm.nih.gov/pubmed/23083343
  • Cannon, M. J., Goyne, H., Stone, P. J., & Chiriva-Internati, M. (2011). Dendritic cell vaccination against ovarian cancer – tipping the Treg/Th17 balance to therapeutic advantage? Expert Opinion on Biological Therapy, 11(4), 441–445. http://doi.org/10.1517/14712598.2011.554812

KTI™

  • Pena, C., Mirandola, L., Figueroa, J. A., Hosiriluck, N., Suvorava, N., Trotter, K., Cobos, E. (2014). Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Annals of Translational Medicine, 2(9), 87. http://doi.org/10.3978/j.issn.2305-5839.2014.09.14
  • Ebrahim, A. H., Alalawi, Z., Mirandola, L., Rakhshanda, R., Dahlbeck, S., Nguyen, D., Chiriva-Internati, M. (2014). Galectins in cancer: carcinogenesis, diagnosis and therapy. Annals of Translational Medicine, 2(9), 88. http://doi.org/10.3978/j.issn.2305-5839.2014.09.12
  • Mirandola, L., Yuefei, Y., Cannon, M. J., Jenkins, M. R., Rahman, R. L., Nguyen, D. D., & Chiriva-Internati, M. (2014). Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecologic Oncology, 135(3), 573-579. doi:10.1016/j.ygyno.2014.09.021 http://www.ncbi.nlm.nih.gov/pubmed/25284038
  • Mirandola, L., Yuefei, Y., Cannon, M. J., Jenkins, M. R., Rahman, R. L., Nguyen, D. D., & Chiriva-Internati, M. (2014). Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecologic Oncology, 135(3), 573-579. doi:10.1016/j.ygyno.2014.09.021 http://www.ncbi.nlm.nih.gov/pubmed/25284038
  • Mirandola, L., Nguyen, D. D., Rahman, R. L., Grizzi, F., Yuefei, Y., Figueroa, J. A., & Chiriva-Internati, M. (2014). Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer?. International Reviews Of Immunology, 33(5), 417-427. doi:10.3109/08830185.2014.911855 http://www.ncbi.nlm.nih.gov/pubmed/24801755
  • Mirandola, L., Yuefei, Y., Kitty, C., Jenkins, M. R., Cobos, E., John, C. M., & Chiriva-Internati, M. (2011). Galectin-3C Inhibits Tumor Growth and Increases the Anticancer Activity of Bortezomib in a Murine Model of Human Multiple Myeloma. Plos ONE, 6(7), 1-14. doi:10.1371/journal.pone.0021811 http://www.ncbi.nlm.nih.gov/pubmed/21765917

Copyright © 2024 Kiromic BioPharma, Inc. All rights reserved.